• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在社区环境中利用快速节俭树进行复杂肿瘤学决策——学术建模与混合建模的作用

Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling.

作者信息

Salgia Ravi, Mambetsariev Isa, Tan Tingting, Schwer Amanda, Pearlstein Daryl P, Chehabi Hazem, Baroz Angel, Fricke Jeremy, Pharaon Rebecca, Romo Hannah, Waddington Thomas, Babikian Razmig, Buck Linda, Kulkarni Prakash, Cianfrocca Mary, Djulbegovic Benjamin, Pal Sumanta K

机构信息

Department of Medical Oncology and Therapeutics Research, 1500 E Duarte Road, City of Hope National Medical Center, Duarte, CA 91010, USA.

Newport Diagnostic Center, Newport Beach, CA 92660, USA.

出版信息

J Clin Med. 2020 Jun 16;9(6):1884. doi: 10.3390/jcm9061884.

DOI:10.3390/jcm9061884
PMID:32560187
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7356888/
Abstract

Non-small cell lung cancer is a devastating disease and with the advent of targeted therapies and molecular testing, the decision-making process has become complex. While established guidelines and pathways offer some guidance, they are difficult to utilize in a busy community practice and are not always implemented in the community. The rationale of the study was to identify a cohort of patients with lung adenocarcinoma at a City of Hope community site (n = 11) and utilize their case studies to develop a decision-making framework utilizing fast-and-frugal tree (FFT) heuristics. Most patients had stage IV (N = 9, 81.8%) disease at the time of the first consultation. The most common symptoms at initial presentation were cough (N = 5, 45.5%), shortness of breath (N = 3, 27.2%), and weight loss (N = 3, 27.2%). The Eastern Cooperative Oncology Group (ECOG) performance status ranged from 0-1 in all patients in this study. Distribution of molecular drivers among the patients were as follows: EGFR (N = 5, 45.5%), KRAS (N = 2, 18.2%), ALK (N = 2, 18.2%), MET (N = 2, 18.2%), and RET (N = 1, 9.1%). Seven initial FFTs were developed for the various case scenarios, but ultimately the decisions were condensed into one FFT, a molecular stage IV FFT, that arrived at accurate decisions without sacrificing initial information. While these FFT decision trees may seem arbitrary to an experienced oncologist at an academic site, the simplicity of their utility is essential for community practice where patients often do not get molecular testing and are not assigned proper therapy.

摘要

非小细胞肺癌是一种极具破坏性的疾病,随着靶向治疗和分子检测的出现,决策过程变得复杂起来。虽然既定的指南和路径提供了一些指导,但在繁忙的社区医疗实践中难以应用,且在社区中也并非总能得到执行。该研究的基本原理是在希望之城社区站点确定一组肺腺癌患者(n = 11),并利用他们的病例研究来开发一个使用快速节俭树(FFT)启发法的决策框架。大多数患者在首次咨询时处于IV期(N = 9,81.8%)疾病状态。初次就诊时最常见的症状是咳嗽(N = 5,45.5%)、气短(N = 3,27.2%)和体重减轻(N = 3,27.2%)。本研究中所有患者的东部肿瘤协作组(ECOG)体能状态为0 - 1。患者中分子驱动因素的分布如下:表皮生长因子受体(EGFR,N = 5,45.5%)、 Kirsten大鼠肉瘤病毒原癌基因(KRAS,N = 2,18.2%)、间变性淋巴瘤激酶(ALK,N = 2,18.2%)、间质上皮转化因子(MET,N = 2,18.2%)和转染重排(RET,N = 1,9.1%)。针对各种病例情况开发了7个初始FFT,但最终决策被浓缩为一个FFT,即分子IV期FFT,它在不牺牲初始信息的情况下做出了准确决策。虽然这些FFT决策树对于学术机构经验丰富的肿瘤学家来说可能显得随意,但它们效用的简单性对于社区医疗实践至关重要,因为在社区中患者往往无法进行分子检测,也得不到恰当的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f9/7356888/139c0bd88876/jcm-09-01884-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f9/7356888/1a1b8d52e397/jcm-09-01884-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f9/7356888/fb57898a4bb0/jcm-09-01884-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f9/7356888/139c0bd88876/jcm-09-01884-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f9/7356888/1a1b8d52e397/jcm-09-01884-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f9/7356888/fb57898a4bb0/jcm-09-01884-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f9/7356888/139c0bd88876/jcm-09-01884-g003.jpg

相似文献

1
Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling.在社区环境中利用快速节俭树进行复杂肿瘤学决策——学术建模与混合建模的作用
J Clin Med. 2020 Jun 16;9(6):1884. doi: 10.3390/jcm9061884.
2
Heuristic value-based framework for lung cancer decision-making.基于启发式价值的肺癌决策框架。
Oncotarget. 2018 Jul 6;9(52):29877-29891. doi: 10.18632/oncotarget.25643.
3
Transforming clinical practice guidelines and clinical pathways into fast-and-frugal decision trees to improve clinical care strategies.将临床实践指南和临床路径转化为快速且简洁的决策树,以改进临床护理策略。
J Eval Clin Pract. 2018 Oct;24(5):1247-1254. doi: 10.1111/jep.12895. Epub 2018 Feb 27.
4
Towards theory integration: Threshold model as a link between signal detection theory, fast-and-frugal trees and evidence accumulation theory.迈向理论整合:阈值模型作为信号检测理论、快速节俭树与证据积累理论之间的纽带
J Eval Clin Pract. 2017 Feb;23(1):49-65. doi: 10.1111/jep.12490. Epub 2015 Dec 18.
5
Improving methods of clinical practice guidelines: From guidelines to pathways to fast-and-frugal trees and decision analysis to develop individualised patient care.改进临床实践指南的方法:从指南到路径,再到快速简便树和决策分析,以制定个体化的患者护理。
J Eval Clin Pract. 2024 Apr;30(3):393-402. doi: 10.1111/jep.13953. Epub 2023 Dec 10.
6
Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.基于组学的策略在晚期肺癌管理中的评估。
JCO Oncol Pract. 2021 Feb;17(2):e257-e265. doi: 10.1200/OP.20.00117. Epub 2020 Jul 8.
7
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.中国非小细胞肺癌中靶向下一代测序鉴定的驱动基因的基因组特征。
Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.
8
A signal-detection analysis of fast-and-frugal trees.快速节俭树的信号检测分析。
Psychol Rev. 2011 Apr;118(2):316-38. doi: 10.1037/a0022684.
9
Evaluation of a fast-and-frugal clinical decision algorithm ('pathways') on clinical outcomes in hospitalised patients with COVID-19 treated with anticoagulants.评估一种快速简易的临床决策算法(“路径”)对 COVID-19 住院患者接受抗凝治疗的临床结局的影响。
J Eval Clin Pract. 2023 Feb;29(1):3-12. doi: 10.1111/jep.13780. Epub 2022 Oct 13.
10
Fast and frugal trees: translating population-based pharmacogenomics to medication prioritization.快速节俭树:将基于人群的药物基因组学转化为药物优先排序
Per Med. 2015 Mar;12(2):117-128. doi: 10.2217/pme.14.66.

引用本文的文献

1
Using Decision Curve Analysis to Evaluate Testing and/or Predictive Modeling.使用决策曲线分析评估检验和/或预测模型。
Cancer Treat Res. 2023;189:77-84. doi: 10.1007/978-3-031-37993-2_6.
2
Formulating Management Strategies Using Fast-and-Frugal Trees (A Decision Tool to Transform Clinical Practice Guidelines and Clinical Pathways into Decision Support at the Point of Care).运用快速简易决策树制定管理策略(一种将临床实践指南和临床路径转化为即时护理决策支持的决策工具)。
Cancer Treat Res. 2023;189:67-75. doi: 10.1007/978-3-031-37993-2_5.
3
Clinical Network Systems Biology: Traversing the Cancer Multiverse.

本文引用的文献

1
A bright future for KRAS inhibitors.KRAS抑制剂的光明未来。
Nat Cancer. 2020 Jan;1(1):25-27. doi: 10.1038/s43018-019-0016-8.
2
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.免疫疗法和共同突变对KRAS突变型非小细胞肺癌生存的作用。
J Thorac Dis. 2020 Sep;12(9):5086-5095. doi: 10.21037/jtd.2020.04.18.
3
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Summary.无驱动基因改变的IV期非小细胞肺癌的治疗:美国临床肿瘤学会(ASCO)与安大略省卫生厅(OH,安大略癌症中心[CCO])联合指南更新总结
临床网络系统生物学:穿越癌症多元宇宙
J Clin Med. 2023 Jul 7;12(13):4535. doi: 10.3390/jcm12134535.
4
Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience.通过多学科肿瘤学途径整合学术与社区癌症护理及研究以实现基于价值的护理:综述与希望之城的经验
J Clin Med. 2021 Jan 7;10(2):188. doi: 10.3390/jcm10020188.
JCO Oncol Pract. 2020 Aug;16(8):e844-e848. doi: 10.1200/JOP.19.00770. Epub 2020 Feb 24.
4
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.克唑替尼治疗含有 MET 外显子 14 改变的肺癌的抗肿瘤活性。
Nat Med. 2020 Jan;26(1):47-51. doi: 10.1038/s41591-019-0716-8. Epub 2020 Jan 13.
5
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.FLAURA 研究的患者报告结局:奥希替尼对比厄洛替尼或吉非替尼用于治疗表皮生长因子受体突变的晚期非小细胞肺癌患者。
Eur J Cancer. 2020 Jan;125:49-57. doi: 10.1016/j.ejca.2019.11.006. Epub 2019 Dec 12.
7
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
8
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.临床 KRAS(G12C) 抑制剂 AMG 510 可引发抗肿瘤免疫。
Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
9
The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.KRAS 抑制剂 MRTX849 为 KRAS 突变型癌症在小鼠模型和患者中的治疗敏感性提供了新的见解。
Cancer Discov. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28.
10
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.抗 PD-1/PD-L1 免疫疗法在 KRAS 突变型非小细胞肺癌中的优越疗效与炎症表型和增加的免疫原性相关。
Cancer Lett. 2020 Feb 1;470:95-105. doi: 10.1016/j.canlet.2019.10.027. Epub 2019 Oct 20.